# Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

Study · id `cardio:ct-nct02444637` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02444637](<https://clinicaltrials.gov/study/NCT02444637>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02444637

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02444637. Allocation not applicable; no masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2019-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02444637, source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)
- Started: 2015-04 (actual) (ClinicalTrials.gov record NCT02444637, source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)
- Primary completion: 2019-03 (actual) (ClinicalTrials.gov record NCT02444637, source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)
- Completion: 2019-03 (actual) (ClinicalTrials.gov record NCT02444637, source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT02444637, source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02444637-2021-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
- Condition: Alzheimer Disease
- Condition: CVA (Cerebrovascular Accident)
- Intervention (Drug): Rivastigmine
- Lead sponsor: National Neuroscience Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: cb18e5715827a5729f3e0200defba243b64cd3e3293f85dc698ac9befbf38acb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
